Preclinical progression of new organic compounds with targeted biological activity (Q19981): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed label, description and/or aliases in 2 languages: Changing unique label-description pair)
(‎Removed claim: financed by (P890): Directorate-General for Regional and Urban Policy (Q8361), Removing unnecessary financed by statement)
Property / financed by
 
Property / financed by: Directorate-General for Regional and Urban Policy / rank
Normal rank
 

Revision as of 18:10, 28 October 2020

Project Q19981 in Czech Republic
Language Label Description Also known as
English
Preclinical progression of new organic compounds with targeted biological activity
Project Q19981 in Czech Republic

    Statements

    0 references
    92,429,398.75 Czech koruna
    0 references
    3,697,175.95 Euro
    10 January 2020
    0 references
    108,740,469.26 Czech koruna
    0 references
    4,349,618.77 Euro
    10 January 2020
    0 references
    85.0 percent
    0 references
    1 August 2018
    0 references
    31 December 2022
    0 references
    Masarykova univerzita
    0 references
    0 references

    49°12'8.64"N, 16°36'28.44"E
    0 references

    49°11'55.68"N, 16°36'7.06"E
    0 references
    60200
    0 references
    Cílem projektu je optimalizace a preklinická profilace vybraných sloučenin s unikátní biologickou aktivitou s potenciálem vykázat terapeutickou účinnost při minimálních nežádoucích vedlejších účincích v oblasti onkologie a kardiologie. Náplní projektu bude mj. příprava širokého setu sloučenin a důkladné testování biologických a obzvláště farmakologických vlastností, včetně in vivo studií. Vzniklé duševní vlastnictví bude důsledně ošetřeno. Výsledky (TRL3)budou dopracovány s aplikačními firmami. a. (Czech)
    0 references
    The aim of the project is to optimise and preclinical profiling of selected compounds with unique biological activity with the potential to demonstrate therapeutic efficacy in minimal undesirable side effects in the field of oncology and cardiology. The project will include the preparation of a wide set of compounds and thorough testing of biological and especially pharmacological properties, including in vivo studies. The intellectual property generated will be treated consistently. Results (TRL3) will be completed with application companies. a. (English)
    22 October 2020
    0 references

    Identifiers

    CZ.02.1.01/0.0/0.0/16_025/0007381
    0 references